Category: Parkinson's Disease: Neuroimaging
Objective: To investigate imaging and CSF markers of disease pathology associated with anxiety in drug-naïve idiopathic Parkinson’s disease (PD) patients.
Background: Anxiety is a frequent symptom appearing early in PD; however, the underlying neuropathology remains unclear. There are limited studies investigating the aetiology of anxiety in early stages of PD.
Method: The Parkinson’s Progression Markers Initiative database was utilised to identify 423 drug-naïve PD patients. The severity of anxiety was assessed using the State-Trait Anxiety Inventory (STAI) based on the 2 subscales; the State Anxiety Scale (S-Anxiety), which evaluates the current state of anxiety, and the Trait Anxiety Scale (T-Anxiety) which evaluates relatively stable aspects of ‘anxiety proneness’. The relationship between grey matter volumetric loss (regional-based morphometry), microstructural changes (diffusion tensor imaging), and CSF biomarkers with S-Anxiety and T-Anxiety was investigated in limbic regions-of-interest, controlling for age, disease duration and depression (geriatric depression scale). P values were FDR corrected.
Results: Based on a cut-off ≥40 for clinically significant anxiety, the prevalence of S-Anxiety was 25% (n=104) and T-Anxiety was 20% (n=85) in the drug-naïve PD patients. Lower CSF amyloid-β42 levels correlated with higher S-Anxiety (r=-0.14; P=0.007) and T-Anxiety (r=-0.16; P=0.004) scores; while lower α-synuclein (r=-0.16; P=0.004) and total tau (r=-0.14; P=0.008) levels correlated with higher S-Anxiety scores. Higher T-Anxiety was associated with decreased fractional anisotropy in the accumbens (r=-0.19; P=0.018), amygdala (r=-0.19; P=0.019), thalamic primary sensory nuclei (r=-0.19; P=0.020), midbrain (r=-0.18; P=0.021) and the temporal cortex (r=-0.21; P=0.011). Grey matter volumetric loss in the temporal (r=-0.12; P=0.023) and insula (r=-0.12; P=0.015) cortex, midbrain (r=-0.15; P=0.003), median raphe (r=-0.13; P=0.011) and locus coeruleus (r=-0.11; P=0.035) correlated with the severity of T-Anxiety.
Conclusion: These results suggest that in early PD anxiety could be associated with structural and microstructural damage in the limbic system and with abnormal protein accumulation.
To cite this abstract in AMA style:
H. Wilson, E. de Natale, M. Politis. In vivo markers of anxiety in drug-naïve Parkinson’s disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/in-vivo-markers-of-anxiety-in-drug-naive-parkinsons-disease/. Accessed November 25, 2024.« Back to MDS Virtual Congress 2020
MDS Abstracts - https://www.mdsabstracts.org/abstract/in-vivo-markers-of-anxiety-in-drug-naive-parkinsons-disease/